Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Leora Horn

12 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

ECOGTHOS1403

04/26/2016

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)

Treatment

VICCTHO14129

04/13/2016

A Phase III, Open label, Randomised, Multi-centre, International Study of MEDI4736, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC)

Treatment

VICCTHO1595

03/25/2016

An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy

Treatment

VICCTHO1573

02/01/2016

An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Treatment

VICCTHO1556

11/04/2015

A Phase 2 Study of TH-4000 in Patients with EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor

Treatment

VICCTHO1521

10/16/2015

A Phase III, Open-Label, Randomized, Study of MPDL3280A (Anti-PDL1 Antibody) Compared with Gemcitabine + Cisplatin or CARBOPLATIN for PD-L1-Selected, Chemotherapy Naive Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Treatment

VICCTHO1519

10/07/2015

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti−PDL1 Antibody) Compared with Cisplatin or Carboplatin+Pemetrexed for PD-L1−Selected Chemotherapy Naive Patients with Stage Iv Non-Squamous Non−Small Cell Lung Cancer

Treatment

VICCTHO1510

07/09/2015

A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Treatment

VICCTHO1443

03/11/2015

A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Treatment

VICCTHO1478

11/14/2014

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

Treatment

VICCTHO1467

10/02/2014

A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen

Treatment

VICCTHN1244

07/25/2012

Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors